News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
Article in The Guardian describing research into the potential benefits of psychedelic drugs to help those with PTSD, as well as the legal issues that this involves. Featuring comment from Professor David Nutt.
June 11, 2020Magic mushrooms and mental health: could psychedelic drugs treat depression?
Interview with David Nutt, Professor of Neuropsychopharmacology at Imperial College London, where he discusses research, psychedelic drugs, and their potential to treat depression.
May 04, 2020Compass Pathways Secures $80M Series B to Boost Depression Clinical Trial
Article in Crunchbase News provides an overview of Series A and B investment rounds. Featuring a comment from co-founder George Goldsmith, on what this means for COMPASS Pathways.
May 01, 2020Compass raises $80m for treatment-resistant depression drug based on magic mushrooms
Article in PM Live gives a brief overview of how the closing of second round funding will support research and trials involving psychedelic substances.
April 30, 2020Psychedelics Inc.
Article published on Medium giving an overview of startup companies developing treatments with psychedelic drugs. Featuring quotes from co-founder George Goldsmith.
April 30, 2020Compass raises $80M to take magic mushroom drug toward phase 3
Article published in FierceBiotech on the successful closing of our series B finding round, and preparation for phase 3 development. Featuring an interview with co-founder Lars Wilde.
April 28, 2020Mushroom magic draws $80M injection for London-based mental health startup
Endpoints article on our Series B funding round, including interview with our co-founder Lars Wilde.
April 28, 2020Mushrooms work their magic as investors support Compass Pathways start-up
Article in The Times newspaper (UK) on the closing of our Series B funding.
April 18, 2020Are Psychedelics Our Most Promising New Treatments for Depression, Anxiety, and Addiction?
Feature article in Town and Country on the potential of psychedelics in mental health, including an interview with Metten Somers, our principal investigator at one of our clinical trial sites in the Netherlands.
April 17, 2020Pharma’s next strange trip: The industry alters its state of mind on psychedelics
Cover story in Pharma Manufacturing on psychedelics in mental health, including quote from our Vice President of Clinical Operations Sue Stansfield.
March 31, 2020Dr. Ekaterina Malievskaia, COMPASS Pathways: Accelerating Patient Access To Mental Healthcare Innovation
Our Chief Innovation Officer and co-founder, Ekaterina, speaks to Ira Pastor from ideaXme about our story, psychedelics in clinical medicine, and our research in treatment-resistant depression.
March 26, 2020The new psychedelic culture
Our co-founder and Chief Business Officer, Lars, chats to the New Health Club podcast about our company, mental health care in the time of COVID-19, and the future.
March 19, 2020PSYCH: The Psychedelics as Medicine Report
Report profiling the major psychedelic substances, and outlining the current state of associated worldwide regulatory frameworks, clinical trials, and commercial opportunities.
March 18, 2020Navigating Mental Health with Dr Nick Van Terheyden
Podcast with our co-founder Ekaterina and Dr Nick Van Terheyden talking about our journey, our vision and how we are working to achieve it.
March 16, 2020Science, Not Startups: To Thrive in the Long Term, The Psychedelics Industry Needs Less Hype and More Research
Article reiterating the importance of well-conducted scientific studies in psychedelic medicine.
March 11, 2020Exponential: George Goldsmith, Executive Chairman/CEO of COMPASS
Interview with Amanda Lang from Exponential about why our co-founder, George Goldsmith, wants to help the mental health community through innovation.
February 14, 2020Our psychedelic future
Interview with our co-founder Ekaterina with Norwegian publication, Morgenbladet, on our company, our research and our vision for the future.
February 12, 2020Psychedelics move from agents of rebellion towards therapeutics
Article in Nature Medicine on potential of psychedelics, regulatory approval and access to patients.
February 04, 2020Company looking into mental health benefits of magic mushroom compound
Our co-founder George Goldsmith speaks to BNN Bloomberg about COMPASS Pathways, research and improving mental health care.
January 27, 2020Mushrooms for Peter Thiel: how a Russian woman and an American raised $58 million to treat depression with hallucinogens
Our co-founder Ekaterina discusses her story with Forbes Russia, and why she decided to start COMPASS Pathways.
January 17, 2020What Happened To My Mental Health After I Took Acid
Article in Refinery29 on the potential of psychedelics in mental health, including an interview with our co-founder, Ekaterina.
January 16, 2020What it’s like to trip on psilocybin for a scientific research study
Article in New Scientist by Sam Wong, writing about his experience of taking psilocybin as a participant in our study of healthy volunteers at King's College London.
January 08, 2020Shroom-Therapy Startup Edges Toward FDA Approval
Feature in Bloomberg Businessweek on COMPASS, including interview with our co-founders, Ekaterina and George.
December 26, 2019In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle
Endpoints News article on the results of our psilocybin study in healthy volunteers.
December 22, 2019Psilocybin: Four Important Takeaways from a Clinical Trial
Article in Psychology Today on our "pioneering research" conducted at King's College London.
December 17, 2019Interview with our CEO and Co-Founder, George Goldsmith on BioBoss podcast
"The most creative thing in the world for me is just how does an idea get transformed by the people who collect around it." - George Goldsmith
Front page article in the Financial Times reporting on results from COMPASS trial of psilocybin.
Article in The Times on results from our psilocybin trial in healthy volunteers
Further coverage of our psilocybin study conducted by King's College London, published in Newsweek
An overview of the healthy volunteer study with psychedelic drugs at Kings College London, and how COMP360 psilocybin was well tolerated.
October 23, 2019For-profit psychedelics and access for all: a conversation with Ronan Levy of Field Trip Psychedelics
Interview with Ronan Levy in psychedelic Times, discussing for-profit psychedelic drugs in mental healthcare and access for historically under-served communities.
October 19, 2019Investors hope psychedelics are the new cannabis. Are they high?
An article in The Economist about investment in the use of psychedelic drugs for mental health, and the ongoing research in this field.
October 17, 2019Could psychedelic drugs be a cure for depression?
Video featured on Today about how psilocybin may be useful to treat depression, and an overview of the study at John Hopkins University.
October 09, 2019Down the rabbit hole: treating depression with psychedelic drugs
An article in Positive.News about the treatment of depression and other psychiatric disorders with psychedelic drugs. Featuring comment from Chief Innovation Officer and Co-founder Ekaterina Malievskaia.
September 13, 2019Can magic mushrooms really cure depression?
Article in the Telegraph about the potential of psychedelic drugs in the treatment of depression, and an overview of some of the research in the field.
September 06, 2019Psychedelic drug research breaks out of deep freeze as researchers head for the clinic with ambitious trial plans
An Endpoint News article about how the view of psychedelic drugs is changing for clinicians, and their potential to treat psychiatric disorders.
September 04, 2019Johns Hopkins opens new Center for Psychedelic Research
An article in the New York Times about the new center for Psychedelic research at John Hopkins.
September 03, 2019Psychedelic drugs draw some investor attention – and much skepticism
An article from The Wall Street Journal about how a few entrepreneurs and investors see opportunity for novel mental health treatments.
August 17, 2019Psilocybin-assisted mindfulness meditation linked to brain connectivity changes and persisting positive effects
A PsyPost article about how research indicates that psilocybin-assisted mindfulness meditation is associated with changes in brain connectivity, and an altered state of consciousness known as ego death.
August 12, 2019Psilocybin is headed for the mainstream — it’s bringing the problems of big pharma with it
Medium looks at how the psychedelic community is torn over the interest in developing medical versions of a drug that may even be helpful for treatment resistant depression.
July 31, 2019Psychedelic medicine is coming. The law isn’t ready
Article by Scientific American about how the resurgence of psychedelic research has produced its first FDA "breakthrough therapy".
July 29, 2019Researchers: psychedelic microdosing lacks scientific support
Article from Psychiatry & Behavioural Health Learning Network summarising how more preclinical studies exploring the effects of microdosing psychedelics are needed in light of public interest in the practice.
July 05, 2019Are psychedelics going mainstream?
J. Walter Thompson Intelligence piece on how psychedelic drugs are gaining mainstream recognition, from treating depression to achieving a deeper understanding of consciousness.
July 05, 2019Podcast: An interview with Lars Wilde, COMPASS Pathways
COMPASS Pathways Co-founder, Lars Wilde, talks about fundraising on the Worldwide Clinical Trials podcast.
July 04, 2019BIO2019: addressing unmet need in depression
Audio recording of the BIO2019 session on addressing unmet need in depression, which features COMPASS Pathways Co-founder Ekaterina Malievskaia.
June 24, 2019REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics
Research paper by Robin Carhart-Harris and K. J. Friston from the Centre for Psychedelic Research, London, looking at the action of psychedelics by integrating the free-energy principle and entropic brain hypothesis.
Healthline article on whether psilocybin could replace anti-depressant medications.
Bloomberg explores that, as cannabis legalisation spreads across the globe, another mind-altering drug is trying to follow in its tracks: magic mushrooms.
Article from the Guardian about how investing in keeping people well could save many lives and a lot of money.
June 18, 2019‘They broke my mental shackles’: could magic mushrooms be the answer to depression?
Article from The Guardian quoting Co-founder Ekaterina Malievskaia about how psilocybin could work as a reliable treatment for depression.
Article by The Economist about whether the active ingredient in magic mushrooms, psilocybin, offers hope in treating depression.
Feature piece on COMPASS Pathways in Spring edition of Pharmafile.
Research paper by Johns Hopkins University School of Medicine about the results from their recent trial using psilocybin therapy.
May 24, 2019Michael Pollan: not so fast on psychedelic mushrooms
Opinion piece by Michael Pollan on the legalisation of magic mushrooms, for The New York Times.
May 24, 2019Are psychedelic drugs the cure for depression?
Men's Health article about whether psychedelic drugs could be a powerful and viable mental health tool.
May 07, 2019Tim Ferriss just helped launch the world’s first research center dedicated to turning psychedelics into medicines
Business Insider article about the world's first research centre dedicated to turning psychedelics into medicines, where scientists will explore the drugs' potential to treat mental illnesses like depression.
May 07, 2019Psychedelics: mind-enhancing methods to well-being
Panel discussion at Milken Global Conference, featuring researchers, practitioners, and investors on the use of psychedelics in mental health research.
May 03, 2019Psychedelic therapy for depression
Article by The Naked Scientists about FDA breakthrough designation for psilocybin therapy.
February 01, 2019Will MDMA-assisted psychotherapy be covered by health insurance?
Article by Psymposia Magazine on MDMA-assisted psychotherapy, featuring comment by co-founder Ekaterina Malievskaia.
January 16, 2019CBC Radio: psychedelic drugs and the future of psychiatry
Episode on Canadian Broadcasting Corporation programme about psychedelics and mental health, featuring co-founder George Goldsmith.
December 07, 2018Building a Psychedelic Enterprise
Video of an event hosted by UCL Society for the Application of Psychedelics and LSESU Neuroscience Society. COMPASS founders talk about patients, profits, patents and psychedelics.
November 29, 2018Psychedelic Times: Interview with Rick Doblin, Founder and Executive Director, MAPS
Psychedelic Times interviews Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), about psychedelics and capitalism.
November 09, 2018Psilocybin Could Be Legal for Therapy by 2021
"For the first time in U.S. history, a psychedelic drug is on the fast track to getting approved for treating depression by the federal government" - Rolling Stone.
November 05, 2018FDA “Breakthrough” Ruling on Magic Mushrooms, Explained by Scientists
"This is an important advance in bringing these compounds out of the dark ages" - Inverse explains the recent FDA breakthrough therapy designation obtained by COMPASS and what this means.
November 02, 2018Psychedelic Psilocybin Therapy for Depression Granted Breakthrough Therapy Status by FDA
Article from New Atlas covering COMPASS' breakthrough therapy designation, awarded by the FDA, and other psychedelic research.
September 21, 2018Psychedelic drugs to treat depression and PTSD?
WebMD article about MAPS Phase III trial using MDMA to treat PTSD, with mention of COMPASS Pathways' FDA approval.
September 14, 2018Serotonin, psychedelics and psychiatry
Article by Robin Carhart-Harris in World Psychiatry; Official Journal of the World Psychiatric Association, on serotonin, psychedelics and psychiatry.
August 31, 2018The renaissance of psilocybin as a viable treatment option
Article from pharmaceutical-technology.com listing current clinical trials involving psilocybin.
August 23, 2018FDA Approves Psychedelic Magic Mushrooms
The Food and Drug Administration has approved the use of the psychedelic ingredient in magic mushrooms for a drug trial for treatment-resistant depression.
The researchers and renegades are bringing psychedelic drugs into the mental health mainstream. Read more about this feature article in the New York Times by Michael Pollan on psychedelic therapy.
Rob Reid interviews COMPASS founders Katya Malievskaia and George Goldsmith for his After On podcast. They discuss the motivations behind COMPASS as well as the clinical history of psychedelics.
National Public Radio Fresh Air podcast with Michael Pollan on his new book “How to Change Your Mind”.
May 12, 2018Might LSD Be Good For You?
Many psychedelic drugs are non-addictive, and can be helpful in treating all sorts of psychological conditions, argues Michael Pollan. Sam Leith discusses and reviews "How to Change Your Mind: The New Science of Psychedelics" by Michael Pollan.
February 26, 2018Psychedelic healing
Could magic mushrooms help reboot the brain? Article from BBC Focus Magazine focusing on the experience of Kirk Rutter, a participant in the Imperial College psilocybin therapy study.
January 28, 2018Magic Mushrooms May Treat Depression
A trial will assess whether psilocybin, the active ingredient in magic mushrooms, can help. This article is from The Sunday Times about COMPASS Pathways’ trial for treatment-resistant depression.
January 24, 2018Mushrooms emerge from underground
"Magic mushrooms show promise to treat depression and anxiety–and major academic institutions and Silicon Valley are stepping up research and investment. The wellness travel space, in very creative ways, is moving from experiential to truly emotional and transformative travel".
December 08, 2017Peter Thiel’s Bet on Magic Mushrooms
"High-profile Silicon Valley investor Peter Thiel made a bet last year on a company with an unusual idea for treating depression: psychedelics."
November 22, 2017Mind Menders: How Psychedelic Drugs Rebuild Broken Brains
The healing powers of illegal drugs like MDMA and psilocybin are finally living up to the hype – and they are already transforming our view of mental illness.
October 13, 2017Magic mushrooms may reset the brains of depressed patients
A study from Imperial College London demonstrate that patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a 'reset' of their brain activity.
September 10, 2017‘Magic mushrooms’ take a trip into clinical trials
Hundreds of Europeans with depression will soon have the chance to turn on, tune in and drop out of existing drug treatments, in the largest clinical trial ever launched to assess the medicinal effects of a psychoactive substance.
May 17, 2017How magic mushrooms could treat depression
Video and article providing an overview of the use of psilocybin in the treatment of depression, and description of study lead by Robin Carhart-Harris at Imperial College London.
December 30, 2016Psilocybin reduces depression and anxiety in cancer patients
This groundbreaking paper is one of two recent double-blind, placebo-controlled studies with the classic psychedelic, psilocybin, being studied in patients with existential distress associated with a cancer diagnosis.
December 30, 2016Psilocybin can aid cancer patients facing existential distress
Randomized control trial where patients with cancer-related anxiety and depression were given a single dose of psilocybin or control, in conjunction with psychotherapy. Psilocybin was found to produce rapid, robust and enduring anxiolytic and anti-depressant effects.
Can a psychedelic trip change the way people with life-threatening cancer face death? Results from two clinical trials suggest so, as reported in New Scientist.
In two new studies released simultaneously by researchers at New York University and Johns Hopkins, doctors reveal that a single dose of psilocybin—a compound from magic mushrooms—can ease anxiety and depression for up to six months.
Psilocybin has been illegal in the United States for more than 40 years. But Mr. Mihai, who had just finished treatment for Stage 3 Hodgkin’s lymphoma, was participating in a study looking at whether the drug can reduce anxiety and depression in cancer patients.
A single dose of psilocybin, the active ingredient of magic mushrooms, can lift the anxiety and depression experienced by people with advanced cancer for six months or even longer, two new studies show.
August 14, 2016Lifting the veil on psychedelics
Video from a TEDx talk in April 2016 by Robin Carhart-Harris, one of the lead psilocybin researchers at Imperial College London
May 17, 2016Psilocybin with psychological support for treatment-resistant depression
Recent studies have assessed the therapeutic potential of psilocybin for various conditions with promising preliminary results. This study assesses the feasibility of safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression
May 17, 2016‘Magic mushroom’ drug lifts depression in first human trial
An article in Nature News giving an overview of the Imperial College London proof-of-concept study on psilocybin for treatment-resistant depression. Including comments from researchers on the potential of psychedelic drugs to be used for the treatment of psychiatric disorders.
April 25, 2016One Writer’s Trip
A video of journalist Michael Pollan’s autobiographical talk on the altered states of consciousness that certain plants and fungi allow us to achieve.
August 14, 2015Roland Griffiths talks about psilocybin research
Insights from Professor Roland Griffiths into the psilocybin research carried out at Johns Hopkins University looking at anxiety, depression and psychological distress in cancer patients.
August 14, 2015Janeen Delaney’s psilocybin experience
Cancer and anxiety patient, Janeen Delaney, describes her psilocybin experience at Johns Hopkins and the results.
February 09, 2015Real trip treatment
Research into psychedelics, shut down for decades, is now yielding exciting results. In this article from The New Yorker, Michael Pollan presents a considered overview of psychedelic-assisted therapy, its history and its potential benefit to patients.
February 02, 2015‘Magic mushrooms’ and the healing trip
The way in which we commonly perceive so-called magic mushrooms—as the means to youthful psychedelic adventure—is undergoing a radical transformation.
November 29, 2014Can mushrooms treat depression?
"The brains on psilocybin showed radically different connectivity patterns between cortical regions (the parts thought to play an important role in consciousness)".
October 26, 2014Annie Levy’s experience as a psilocybin study participant
Video clip from the Heffter Research Institute published in 2014. Cancer patient Annie Levy describes her psilocybin experience at Harbor-UCLA Medical Center and the results.
April 11, 2010Hallucinogens have doctors tuning in again
Scientists are taking a new look at hallucinogens, which became taboo among regulators after enthusiasts like Timothy Leary promoted them in the 1960s with the slogan “Turn on, tune in, drop out”.